Ki Summary

Reaction Details

Report a problem with these data

Target

Kappa-type opioid receptor

Ligand

BDBM50292925

Substrate/Competitor

n/a

Meas. Tech.

ChEMBL_495340 (CHEMBL1006332)

1013±n/a nM

Citation

Li, G; Aschenbach, LC; Chen, J; Cassidy, MP; Stevens, DL; Gabra, BH; Selley, DE; Dewey, WL; Westkaemper, RB; Zhang, Y Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem52:1416-27 (2010) [PubMed] Article

More Info.:

Get all data from this article, Assay Method

Kappa-type opioid receptor

Name:

Kappa-type opioid receptor

Synonyms:

Type:

G Protein-Coupled Receptor (GPCR)

Mol. Mass.:

42648.76

Organism:

Homo sapiens (Human)

Description:

P41145

Residue:

380

Sequence:

MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL
MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI
CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL
IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG
STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV
RNTVQDPAYLRDIDGMNKPV

BDBM50292925

n/a

Name

BDBM50292925

Synonyms:

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(3-guanidinopropyl)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-((R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide | CHEMBL525046

Type

Small organic molecule

Emp. Form.

C52H69N13O11S2

Mol. Mass.

1116.315

SMILES

C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC1(C)C)NC(=O)[C@H]1Cc2ccccc2CN1)[C@@H](C)O)C(N)=O |r,wU:7.6,52.62,72.79,62.65,wD:3.3,1.1,40.42,26.26,15.15,11.77,(48.26,5.04,;48.26,6.58,;49.59,7.35,;46.94,7.35,;45.6,6.58,;45.6,5.04,;46.94,4.27,;44.31,4.21,;44.37,2.53,;45.7,1.73,;47.03,2.49,;45.68,.2,;44.35,-.59,;43.01,.19,;43.01,-1.36,;41.59,-.59,;41.59,-2.12,;42.92,-2.89,;42.92,-4.43,;44.25,-5.19,;44.25,-6.74,;42.92,-7.51,;45.58,-7.51,;40.35,.19,;39.02,-.58,;39.02,-2.11,;37.69,.19,;37.69,-2.27,;36.36,-3.03,;34.91,-2.41,;33.89,-3.64,;34.63,-4.9,;34.16,-6.36,;35.19,-7.52,;36.71,-7.23,;37.22,-5.75,;36.16,-4.56,;36.36,-.57,;35.02,.2,;35.02,-1.34,;33.68,-.57,;33.68,-2.57,;32.15,-3.85,;30.69,-3.31,;29.5,-4.31,;29.79,-5.85,;28.62,-6.85,;31.23,-6.37,;32.42,-5.37,;32.36,.21,;30.96,-.54,;30.62,-2.04,;29.66,.31,;29.71,1.78,;34.37,3.93,;42.28,3.53,;42.95,4.89,;41.58,5.57,;43.64,6.26,;28.29,-.41,;26.96,.36,;26.96,1.91,;25.63,-.41,;25.63,-1.9,;24.29,-2.67,;24.29,-4.24,;23,-4.98,;21.72,-4.24,;21.64,-2.73,;22.96,-1.97,;22.96,-.41,;24.25,.4,;47.01,-.57,;48.34,.2,;47.01,-2.11,;46.94,8.89,;45.6,9.67,;48.26,9.67,)|

Structure